Preclinical Imaging Market

The report "Preclinical Imaging Market by Product Type (Optical Imaging (Bioluminescance), PET, SPECT, MRI, Optical Imaging Reagents (Infrared Dyes), Software), Application (Oncology, Neurology), End User (Pharma, Imaging Centers) & Region - Global Forecast to 2029", is projected to reach USD 5,101 million by 2029 from USD 3,997 million in 2024, at a CAGR 5.0%.

Browse 1000 market data Tables and 44 Figures spread through 591 Pages and in-depth TOC on "Preclinical Imaging Market by Product Type (Optical Imaging (Bioluminescance), PET, SPECT, MRI, Optical Imaging Reagents (Infrared Dyes), Software), Application (Oncology, Neurology), End User (Pharma, Imaging Centers) & Region - Global Forecast to 2029 "
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/pre-clinical-molecular-imaging-market-841.html

The growth in the preclinical imaging market is driven by the increasing funding to support preclinical researches, development of low-cost & affordable preclinical imaging systems ,and increasing market demand for new drug development and noninvasive small-animal imaging techniques.

Optical Imaging reagents segment is the largest product type of the preclinical reagents market in 2023.

Based on reagents, the preclinical imaging market is segmented into optical imaging reagents, nuclear imaging reagents, MRI contrast agents, ultrasound contrast agents, and CT contrast agents. Among these, optical imaging reagents segment accounted for the largest share of the preclinical imaging market market in 2023. The large market share of the optical imaging reagents segment is attributed to the high penetration of optical imaging modalities in preclinical research studies

Oncology segment is the largest application of the preclinical imaging market in 2023.

Based on application, the preclinical imaging market is segmented into oncology, cardiology, neurology, infectious diseases, immunology and inflammation, and other applications. In 2023, oncology segment accounted for the largest share of the market. This can be due to as oncology benefits greatly from advancements in molecular imaging, allowing researchers to target specific biomarkers associated with cancer cells. This provides valuable insights into tumor biology and drug targeting.

By end user, pharmaceutical & biotechnology companies are the largest end user in the brain preclinical imaging market in 2023.

Based on end user, the preclinical imaging market is segmented into pharmaceutical & biotechnology companies, academic and research centers, imaging centers, and other end users. In 2023, the pharmaceutical & biotechnology companies segment accounted for the largest share in the market. The volume of research and development work conducted by these companies has increased significantly, accompanied by a rise in investment for these activities. The ongoing need for advanced drugs will continue to drive demand for research and development efforts. Biotechnology companies utilize this technology extensively due to its wide range of applications.

North America dominates the global preclinical imaging market in 2023.

The preclinical imaging market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America is anticipated to dominate the preclinical imaging market due to its developed infrastructure, numerous preclinical projects, and higher adoption rates of advanced technological devices in the region.

Key Players

Prominent players in the preclinical imaging market include MR Solutions (UK), Mediso Ltd. (UK), Sofie (US), Fujifilm Visual Sonics (Canada), MILABS B.V. (Netherlands), Aspect Imaging Limited (US), Li-Cor Biosciences (US), ICONEUS (Paris), Advanced Molecular Vision (UK), Viewworks (Korea), Kub Technologies (US), Medikor (US), Trifoil Imaging (US), IVIM Technology Corp. (South Korea), Cubresa, Inc. (Canada), Berthold Technologies GMBH & CO.KG (Germany), Miltenyi Biotech GmbH (Germany), AI4R (France), Bruker Corporation (US), and Revvity, Inc. (US).

Don’t miss out on business opportunities in Preclinical Imaging Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]